Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined whether canagliflozin decreases albuminuria and reduces renal function decline independently of its glycemic effects in a secondary analysis of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6–8 mg. End points were annual change in eGFR and albuminuria over 2 years of follow-up. Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/min per 1.73 m 2 per year (95% confidence interval [95% CI], 2.8 to 3.8), 0.5 ml/min per 1.73 m 2 per year (95% CI, 0.0 to 1.0), and 0.9 ml/min per 1.73 m 2 per year (95% CI, 0.4 to 1.4), respectively ( P <0.01 for each canagliflozin group versus glimepiride). In the subgroup of patients with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, urinary albumin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P =0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P <0.001) than with glimepiride. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years. In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride, slowed the progression of renal disease over 2 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independently of its glycemic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia (31,(97)(98)(99)(100)(101).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [98]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Research works printed but not linked: 1
- 2015, Standards of medical care in diabetes–2015., Diabetes Care, 38, S1
Cited by
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Self-citationGlobal kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Self-citationPerkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Self-citationVallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
“Following this initial dip, eGFR declined at a slower rate in the canagliflozin-treated group such that it was better preserved after 2 years of follow-up and associated with reduced urinary albumin:creatinine ratio, as compared with a control group that had been treated with glimepiride to achieve similar blood gluco…”
ResultInfluentialMechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
“A similar GFR time course was observed in clinical studies with canagliflozin (10, 49, 50) and dapagliflozin (51).”
ResultThe tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Self-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Self-citationCherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Development of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
“This may reduce K+ retention in diabetic individuals with CKD and enhance the tolerability of AngII blockade and thus allow their continued use, which is expected to be of therapeutic benefit [30].”
InfluentialThe actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
“This is supported by head-to-head studies with other glucoselowering agents that show that SGLT2 inhibitors preserve kidney function, independent of glycaemic control.(102) SGLT2 inhibition in the proximal tubule increases distal sodium delivery, which in turn stimulates tubuloglomerular feedback to promote afferent a…”
Self-citationHeerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Garcia Rodriguez, L. A., Cea-Soriano, L., Kohsaka, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30384-5 · Cited by 317
Self-citationThe Impact of CKD on Uremic Toxins and Gut Microbiota
Rysz, J., Franczyk, B., Ławiński, J., Olszewski, R., Ciałkowska-Rysz, A., & Gluba-Brzózka, A. (2021) · Toxins · doi:10.3390/toxins13040252 · Cited by 307
“Other studies also indicated canagliflozin-related slowing of renal function decline progression independently of glycemic effects [164,165].”
Result10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Cherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283
Self-citationPost-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13301 · Cited by 263
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Self-citationHerrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
“Canagliflozin 100–300 mg/day has been compared with the sulfonylurea glimepiride in 1450 people with T2DM [72].”
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationInsights into Glomerular Filtration and Albuminuria
Benzing, T., & Salant, D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1808786 · Cited by 213
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Self-citationModelling diabetic nephropathy in mice
Azushima, K., Gurley, S. B., & Coffman, T. M. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.142 · Cited by 209
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“These effects of SGLT-2 inhibitors on reduction of glomerular hyperfiltration and intraglomerular pressure are supported by the EMPA-REG OUTCOME and CANVAS trials, as well as several other studies, showing decrease in urine albumin excretion [97, 98].”
ResultPollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30086-5 · Cited by 205
Self-citationDiabetic Kidney Disease: Challenges, Advances, and Opportunities
Chen, Y., Lee, K., Ni, Z., & He, J. C. (2020) · Kidney Diseases · doi:10.1159/000506634 · Cited by 200
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
“Results from CANTATA-SU secondary analysis showed that compared with glimepiride, canagliflozin slowed the progression of renal disease over 2 years, and that it may confer renoprotective effects independent of its glycemic effects [92].”
Method10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Cassis, P., Locatelli, M., Cerullo, D., Corna, D., Buelli, S., Zanchi, C., Villa, S., Morigi, M., Remuzzi, G., Benigni, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98720 · Cited by 173
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
van der Aart-van der Beek, A. B., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 173
Self-citationOshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050723 · Cited by 176
“The 26-week exposure window was chosen because it was the first time point at which follow-up UACR measurements were available and prior studies have shown that the UACR-lowering effect of canagliflozin is fully present at that time point.(8,11)”
MethodResultSelf-citationNeal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12829 · Cited by 174
Self-citationSGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051083 · Cited by 168
“A secondary analysis of the Canagliflozin Treatment and Trial Analysis versus Sulphonylurea (CANTA-SU) study confirmed the renoprotective effects of canagliflozin [43].”
BackgroundResultJardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., Bajaj, H. S., Bull, S., Cannon, C. P., Charytan, D. M., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019111168 · Cited by 168
Self-citationRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“8]).[206] The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk.”
MethodMann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157
Xie, Y., Bowe, B., Gibson, A. K., McGill, J. B., Maddukuri, G., Yan, Y., & Al-Aly, Z. (2020) · Diabetes Care · doi:10.2337/dc20-1890 · Cited by 153
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Tang, L., Wu, Y., Tian, M., Sjöström, C. D., Johansson, U., Peng, X.-R., Smith, D. M., & Huang, Y. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00086.2017 · Cited by 162
“Interestingly, regression analyses indicate that the glucose-lowering effects of dapagliflozin are accountable only for a smaller proportion of the overall effect on albuminuria (8, 14, 15).”
BackgroundGroop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13041 · Cited by 149
“In general, it is likely that ubiquitous albuminuria-lowering effects over the short term may be achieved only by haemodynamic interventions that actively lower glomerular pressure, such as RAAS blockers and, possibly, SGLT2 inhibitors such as empagliflozin,(31) dapagliflozin(32) or canagliflozin.(33) The small mean r…”
BackgroundSelf-citationGlucose transporters in the kidney in health and disease
Vallon, V. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02361-w · Cited by 161
Laxmikeshav, K., Pooja, K., & Shankaraiah, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21852 · Cited by 156
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
Self-citationSGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.03.022 · Cited by 135
Schwaiger, E., Burghart, L., Signorini, L., Ristl, R., Kopecky, C., Tura, A., Pacini, G., Wrba, T., Antlanger, M., Schmaldienst, S., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15223 · Cited by 133
“Diastolic blood pressure mm Hg, mean (SD) 86 (14) — 84 (16) — 71 (11) 76 (11) .”
Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss
Zewinger, S., Rauen, T., Rudnicki, M., Federico, G., Wagner, M., Triem, S., Schunk, S. J., Petrakis, I., Schmit, D., Wagenpfeil, S., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040405 · Cited by 125
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B., & Tuttle, K. R. (2019) · Diabetes · doi:10.2337/dbi18-0007 · Cited by 121
“001), respectively, despite similar glycemic control (46).”
BackgroundHeerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P., Correa-Rotter, R., Kurlyandskaya, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab094 · Cited by 121
“8,9 These findings have led to the hypothesis that SGLT2 inhibitors may also preserve kidney function in patients with CKD without Type 2 diabetes.”
Self-citationTherapeutic Advances in Diabetic Nephropathy
Sawaf, H., Thomas, G., Taliercio, J. J., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020378 · Cited by 130
“In addition, studies have shown that SGLT2 inhibitors can simulate antioxidant and antiinflammatory signaling pathways [20], which can potentially reverse molecular processes related to inflammation, extracellular matrix turnover, and fibrosis [21].”
BackgroundMitochondria in Diabetic Kidney Disease
Ahmad, A. A., Draves, S. O., & Rosca, M. G. (2021) · Cells · doi:10.3390/cells10112945 · Cited by 126
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
Self-citationPetrykiv, S. I., Laverman, G. D., de Zeeuw, D., & Heerspink, H. J. L. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12936 · Cited by 105
“This finding is in accordance with a previous post-hoc analysis from a large randomized controlled trial demonstrating that long-term effects of the SGLT2 inhibitor canagliflozin on renal function are independent of its glycaemic effects.(14) What could be the mechanism of the albuminuria-lowering effect? As observed…”
ResultSelf-citationDas, N. A., Carpenter, A. J., Belenchia, A. M., Aroor, A. R., Noda, M., Siebenlist, U. K., Chandrasekar, B., & DeMarco, V. G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109506 · Cited by 113
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 129
“A reduction in eGFR decline was also observed with empagliflozin use in this trial 60 and in a trial of canagliflozin in which decline in eGFR was the primary outcome 73 .”
Self-citationMishima, E., Fukuda, S., Kanemitsu, Y., Saigusa, D., Mukawa, C., Asaji, K., Matsumoto, Y., Tsukamoto, H., Tachikawa, T., Tsukimi, T., et al. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2017 · Cited by 112
“Recently, canagliflozin was reported to slow the progression of renal function decline independently of glycemic effects (15, 36).”
BackgroundeGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
Meraz-Muñoz, A., Weinstein, J. J., & Wald, R. (2021) · Kidney360 · doi:10.34067/kid.0001172021 · Cited by 121
“73m(2)) shortly after initiating these drugs compared to placebo controls (5,8,9,11,12).”
BackgroundInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Self-citationNew therapeutic targets in chronic kidney disease progression and renal fibrosis
Rayego‐Mateos, S., & Valdivielso, J. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762173 · Cited by 113
“Similar results regarding the improvement of renal function (eGFR or albuminuria) were obtained in the CANTA-SU study in T2DM patients who receive metformin and were treated with a different SGLT2 inhibitor (canagliflozin) [13].”
ResultRådholm, K., Wu, J. H., Wong, M. G., Foote, C., Fulcher, G., Mahaffey, K. W., Perkovic, V., & Neal, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.027 · Cited by 94
Self-citationKelly, M. S., Lewis, J., Huntsberry, A. M., Dea, L., & Portillo, I. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1549459 · Cited by 94
“One of these post-hoc analysis evaluated SGLT2-I vs glimepiride [24], while the other evaluated SGLT2-I vs placebo [23].”
BackgroundMethodDiabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath, K. L., & Edi, R. (2019) · PubMed · Cited by 127
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49525-y · Cited by 106
Chen, J., Fan, F., Wang, J. Y., Long, Y., Gao, C. L., Stanton, R. C., & Xu, Y. (2017) · Scientific Reports · doi:10.1038/srep44128 · Cited by 91
Levin, A., Perkovic, V., Wheeler, D. C., Hantel, S., George, J. T., von Eynatten, M., Koitka-Weber, A., Wanner, C., & on behalf of the EMPA-REG OUTCOME Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14901219 · Cited by 90
“A similar finding was reported with canagliflozin (28).”
ResultSelf-citationSGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 106
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 93
Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis
Cahn, A., Melzer‐Cohen, C., Pollack, R., Chodick, G., & Shalev, V. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13532 · Cited by 85
“Similar cardioprotective and renal protective findings have recently been reported with canagliflozin in the CANagliflozin cardioVascular Assessment Study (CANVAS) trial, suggesting the possibility of a class effect.(3,4) However, concern has been raised regarding the possibility of an increased risk of acute renal fa…”
ResultThe Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Patel, D. K., & Strong, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 79
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22229-5 · Cited by 73
Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002050 · Cited by 72
“However, in one [23] of these studies, the authors presented the investigated outcomes separately in the subgroup of the overall population with UACR at least 30mg/g.”
ResultKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 81
Self-citationCardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 81
“These effects may result in an acute decrease in albuminuria and eGFR, followed by eGFR stability in the long run (56).”
BackgroundAlaini, A., Malhotra, D. K., Rondon‐Berrios, H., Argyropoulos, C., Khitan, Z. J., Raj, D. S., Rohrscheib, M. R., Shapiro, J. I., & Tzamaloukas, A. H. (2017) · World Journal of Methodology · doi:10.5662/wjm.v7.i3.73 · Cited by 74
Wakisaka, M., & Nagao, T. (2017) · Glycobiology · doi:10.1093/glycob/cwx047 · Cited by 66
“However, the contribution of TGF to the renoprotective effect of SGLT2 inhibitors is controversial (Faulhaber-Walter et al. 2008; Heerspink et al. 2017).”
BackgroundInfluentialSeidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 97
“…of T2DM, SGLT2is are associated with reduced CVD, renal disease and HF, delivering health gain as well as cost sav‑ ings via reduced resource utilisation and effec‑ tive management of complications and releas‑ ing capacity within the system [3, 4, 17–22, 28, 29, 31, 41, 44, 53, 55, 56, 75–77].”
Gong, P., Cui, D., Guo, Y., Wang, M., Wang, Z., Huang, Z., Yang, W., Chen, F., & Chen, X. (2021) · Food & Function · doi:10.1039/d1fo01182k · Cited by 62
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 70
Inoue, M.-K., Matsunaga, Y., Nakatsu, Y., Yamamotoya, T., Ueda, K., Kushiyama, A., Sakoda, H., Fujishiro, M., Ono, H., Iwashita, M., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0454-6 · Cited by 61
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.007 · Cited by 57
“Meta-analyses of clinical trial data suggest that a 30% reduction in albuminuria was associated with a 24% reduction in the risk of endstage renal disease,(34) assuming other markers of kidney disease were stable.(27) Reductions in vascular stiffness(35,36) and vascular resistance(35) associated with SGLT2 inhibitor t…”
BackgroundMethodResultInfluentialSodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Dekkers, C. C. J., & Gansevoort, R. T. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz264 · Cited by 61
Canagliflozin: A Review in Type 2 Diabetes
Deeks, E. D., & Scheen, A. J. (2017) · Drugs · doi:10.1007/s40265-017-0801-6 · Cited by 66
“In a post hoc analysis [49] of the glimepiride-controlled trial [43], canagliflozin also appeared to preserve renal function relative to glimepiride over 104 weeks.”
BackgroundMethodEMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.012 · Cited by 74
Drug repurposing in kidney disease
Panchapakesan, U., & Pollock, C. A. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.026 · Cited by 57
Jardine, M., Zhou, Z., Heerspink, H. J. L., Hockham, C., Li, Q., Agarwal, R., Bakris, G. L., Cannon, C. P., Charytan, D. M., Greene, T., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15260920 · Cited by 60
Self-citationTsai, W.-C., Hsu, S.-P., Chiu, Y.-L., Yang, J.-Y., Pai, M.-F., Ko, M.-J., Tu, Y.-K., Hung, K.-Y., Chien, K.-L., Peng, Y.-S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060655 · Cited by 53
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Metadata
- Authors
- Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V.
- Affiliations
- University Medical Center Groningen (NL)
- Janssen Research & Development (United States) (US)
- The University of Sydney (AU)
- Corresponding author
- Heerspink, Hiddo J. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-08-18
- Volume
- 28
- Issue
- 1
- Pages
- 368-375
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC5198289
- OpenAlex
- W2512006388
- Cited by
- 361
- References
- 22
- Citations by year
- 2026: 30 · 2025: 14 · 2024: 17 · 2023: 28 · 2022: 28 · 2021: 44 · 2020: 41 · 2019: 49 · 2018: 49 · 2017: 51 · 2016: 10
- FWCI
- 53.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, renal function decline, EGFR, albuminuria, glimepiride, metformin, renal protection, glycemic control, albumin-creatinine ratio, dose-response relationship, diabetic nephropathy, secondary prevention, cardiovascular risk reduction, HbA1c
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfonylurea Compounds, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.